{"transactions":[{"id":1294421,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T18:04:15.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":91300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":91300,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":91300},"source":{"system":"sec-edgar","filing":"0001746473-25-000013","document":"wk-form4_1738019047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647325000013/wk-form4_1738019047.xml","form_type":"4"}},{"id":1294420,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:04:15.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":45650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":240224,"source":{"system":"sec-edgar","filing":"0001746473-25-000013","document":"wk-form4_1738019047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647325000013/wk-form4_1738019047.xml","form_type":"4"}},{"id":1297527,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-22T18:00:36.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":18478,"price":11.2011,"value":206973.9258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":194574,"source":{"system":"sec-edgar","filing":"0001746473-25-000003","document":"wk-form4_1737586829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647325000003/wk-form4_1737586829.xml","form_type":"4"}},{"id":1455318,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-12T18:45:16.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":12319,"price":11.56,"value":142407.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":213052,"source":{"system":"sec-edgar","filing":"0001746473-24-000129","document":"wk-form4_1720824309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647324000129/wk-form4_1720824309.xml","form_type":"4"}},{"id":1456155,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-11T17:01:03.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":24063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which were subject to the achievement of various  pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 24,063 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":225371,"source":{"system":"sec-edgar","filing":"0001746473-24-000119","document":"wk-form4_1720731654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647324000119/wk-form4_1720731654.xml","form_type":"4"}},{"id":1563863,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T17:05:48.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0000950170-24-035468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035468/ownership.xml","form_type":"4"}},{"id":1563862,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T17:05:48.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-035468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035468/ownership.xml","form_type":"4"}},{"id":1563861,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T17:05:48.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":115000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.21,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0000950170-24-035468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035468/ownership.xml","form_type":"4"}},{"id":1669898,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-26T18:16:29.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":14010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2024."}],"balance_after":14010,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0001062993-24-001418","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001418/form4.xml","form_type":"4"}},{"id":1672004,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T16:58:02.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":85800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":85800,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":85800},"source":{"system":"sec-edgar","filing":"0001746473-24-000017","document":"wk-form4_1706133471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647324000017/wk-form4_1706133471.xml","form_type":"4"}},{"id":1672003,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-24T16:58:02.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":42900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":199820,"source":{"system":"sec-edgar","filing":"0001746473-24-000017","document":"wk-form4_1706133471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647324000017/wk-form4_1706133471.xml","form_type":"4"}},{"id":1675177,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-19T17:18:57.000Z","date":"2024-01-17","kind":"sale","planned":true,"acquired":false,"shares":10295,"price":17.23,"value":177382.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, o between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":156920,"source":{"system":"sec-edgar","filing":"0001746473-24-000002","document":"wk-form4_1705702729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647324000002/wk-form4_1705702729.xml","form_type":"4"}},{"id":1826844,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-07-19T20:29:01.000Z","date":"2023-07-17","kind":"sale","planned":true,"acquired":false,"shares":22321,"price":18.0091,"value":401981.1211,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":167215,"source":{"system":"sec-edgar","filing":"0001209191-23-042831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919123042831/doc4.xml","form_type":"4"}},{"id":1827791,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-07-18T19:22:23.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 43,750 shares."}],"balance_after":189536,"source":{"system":"sec-edgar","filing":"0001209191-23-042660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919123042660/doc4.xml","form_type":"4"}},{"id":1932357,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-03T19:01:25.000Z","date":"2023-03-30","kind":"sale","planned":true,"acquired":false,"shares":11245,"price":26.5209,"value":298227.5205,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":145786,"source":{"system":"sec-edgar","filing":"0001209191-23-022374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919123022374/doc4.xml","form_type":"4"}},{"id":1933930,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-31T18:02:11.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":21874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,874 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":157031,"source":{"system":"sec-edgar","filing":"0001209191-23-021921","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919123021921/doc4.xml","form_type":"4"}},{"id":2043684,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-27T19:15:26.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":80000,"derivative":{"exercise_price":34.65,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001140361-23-003178","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000114036123003178/form4.xml","form_type":"4"}},{"id":2043683,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-27T19:15:26.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":133926,"source":{"system":"sec-edgar","filing":"0001140361-23-003178","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000114036123003178/form4.xml","form_type":"4"}},{"id":2043970,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-27T16:33:22.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2023."}],"balance_after":25000,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-23-001495","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323001495/form4.xml","form_type":"4"}},{"id":2046377,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:00:38.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":67500,"price":34.4834,"value":2327629.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022."}],"balance_after":76926,"source":{"system":"sec-edgar","filing":"0001140361-23-002784","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000114036123002784/form4.xml","form_type":"4"}},{"id":2078794,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-21T21:32:36.000Z","date":"2022-12-20","kind":"sale","acquired":false,"shares":10887,"price":19.1024,"value":207967.8288,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":144426,"source":{"system":"sec-edgar","filing":"0001140361-22-046569","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000114036122046569/form4.xml","form_type":"4"}},{"id":2078793,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-12-21T21:32:36.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":21876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,876 shares."}],"balance_after":155313,"source":{"system":"sec-edgar","filing":"0001140361-22-046569","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000114036122046569/form4.xml","form_type":"4"}},{"id":2130989,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T21:05:04.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":5000,"price":25.0482,"value":125241.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.27, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1 share of Common Stock acquired by the reporting person pursuant to an employee stock purchase program."}],"balance_after":133437,"source":{"system":"sec-edgar","filing":"0001209191-22-054747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919122054747/doc4.xml","form_type":"4"}},{"id":2208028,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-07-13T19:06:38.000Z","date":"2022-07-11","kind":"sale","acquired":false,"shares":3000,"price":20,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,356 shares of Common Stock acquired by the reporting person pursuant to an employee stock purchase program."}],"balance_after":138436,"source":{"system":"sec-edgar","filing":"0001567619-22-013995","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000156761922013995/doc1.xml","form_type":"4"}},{"id":2323378,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-21T17:40:56.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/36 of the underlying shares monthly from March 21, 2022."}],"balance_after":115000,"derivative":{"exercise_price":3.21,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001062993-22-008214","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299322008214/form4.xml","form_type":"4"}},{"id":2416634,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T20:13:25.000Z","date":"2022-01-26","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":140000,"derivative":{"exercise_price":11.86,"expiration_date":"2032-01-25","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001567619-22-002398","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000156761922002398/doc1.xml","form_type":"4"}},{"id":2658792,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-22T19:52:43.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":22,"price":30.23,"value":665.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."}],"balance_after":137080,"source":{"system":"sec-edgar","filing":"0001209191-21-042577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919121042577/doc4.xml","form_type":"4"}},{"id":2658791,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-22T19:52:43.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":3728,"price":29.4308,"value":109718.0224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.2000 to $29.8500, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":137102,"source":{"system":"sec-edgar","filing":"0001209191-21-042577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919121042577/doc4.xml","form_type":"4"}},{"id":2658790,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-22T19:52:43.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":8750,"price":28.6215,"value":250438.125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.2000 to $29.1900, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":140830,"source":{"system":"sec-edgar","filing":"0001209191-21-042577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919121042577/doc4.xml","form_type":"4"}},{"id":2777597,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-19T19:09:36.000Z","date":"2021-03-18","kind":"sale","acquired":false,"shares":1135,"price":39.7799,"value":45150.1865,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.72 to $39.84, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":149580,"source":{"system":"sec-edgar","filing":"0001209191-21-022161","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919121022161/doc4.xml","form_type":"4"}},{"id":2777596,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-19T19:09:36.000Z","date":"2021-03-18","kind":"sale","acquired":false,"shares":11365,"price":39.3777,"value":447527.5605,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.72 to $39.70, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":150715,"source":{"system":"sec-edgar","filing":"0001209191-21-022161","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919121022161/doc4.xml","form_type":"4"}},{"id":2895163,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-26T20:00:15.000Z","date":"2021-01-23","kind":"grant","acquired":true,"shares":73250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":73250,"derivative":{"exercise_price":26.5,"expiration_date":"2031-01-22","underlying":"Common Stock","underlying_shares":73250},"source":{"system":"sec-edgar","filing":"0000899243-21-003381","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000089924321003381/doc4.xml","form_type":"4"}},{"id":2936219,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-21T20:00:07.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":5712,"price":26.98,"value":154109.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.57 to $27.41, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":162080,"source":{"system":"sec-edgar","filing":"0000899243-20-034780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000089924320034780/doc4.xml","form_type":"4"}},{"id":2936218,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-21T20:00:07.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":6788,"price":26.17,"value":177641.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.57 to $26.56, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":167792,"source":{"system":"sec-edgar","filing":"0000899243-20-034780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000089924320034780/doc4.xml","form_type":"4"}},{"id":4567817,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:23:03.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":101000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.91,"expiration_date":"2026-01-12","underlying":"Common Stock","underlying_shares":101000},"source":{"system":"sec-edgar","filing":"0001209191-16-148099","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919116148099/doc4.xml","form_type":"4"}},{"id":4567816,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:23:03.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2025-05-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-16-148099","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919116148099/doc4.xml","form_type":"4"}},{"id":4567815,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:23:03.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":79287,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.51,"expiration_date":"2022-02-15","underlying":"Common Stock","underlying_shares":79287},"source":{"system":"sec-edgar","filing":"0001209191-16-148099","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000120919116148099/doc4.xml","form_type":"4"}}]}